Summit continues to make strong progress with its DMD utrophin modulation and C. difficile (CDI) programmes with important development milestones from both expected in H1 CY 2018. Interim 24 week data from the PhaseOut DMD trial is expected in Q1 2018 (we provide an overview of the trial in this note) and the Phase III programme for ridinilazole (for the treatment of CDI) is on track to commence in H1 2018. In Q3 Summit reported positive top-line data from its exploratory Phase II trial evaluati ....
06 Dec 2017
N+1 Singer - Summit Therapeutics - Q3 results; interim PhaseOut DMD data due Q1 2018
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Summit Therapeutics - Q3 results; interim PhaseOut DMD data due Q1 2018
Summit continues to make strong progress with its DMD utrophin modulation and C. difficile (CDI) programmes with important development milestones from both expected in H1 CY 2018. Interim 24 week data from the PhaseOut DMD trial is expected in Q1 2018 (we provide an overview of the trial in this note) and the Phase III programme for ridinilazole (for the treatment of CDI) is on track to commence in H1 2018. In Q3 Summit reported positive top-line data from its exploratory Phase II trial evaluati ....